Visit www.oncologyGPS.com In the realm of cells and silent battles, Where life's essence weaves and rattles, A companion emerges, not of flesh, but code, A sentinel in the healing abode. **AI, the ally, with algorithms so bright,** **Crafting diagnostics in the absence of light.** It reads the patterns, the data it gleans, To unveil the unseen, in binary streams. With each scan and sample, it learns, Through neural networks, it discerns. The malign from benign, the chaff from the wheat, In its silicon mind, no cancer can cheat. **Prognostics it renders, with precision so keen,** **A digital oracle, on the screen.** Predicting outcomes, charting the course, Guiding the doctors with gentle force. In the fight against cancer, a formidable foe, This AI companion, a beacon does glow. A tool of hope, in the darkest night, Shining the path, towards health and light.
Oncology GPS: A companion for cancer diagnostics
More Relevant Posts
-
Visit us at www.OncologyGPS.com In the realm of healing, where hope is a seed, Generative AI sows, with precision and speed. A digital gardener, in data's vast field, Cultivating cures, with algorithms wielded. In oncology's fight, against the shadowed foe, AI's influence grows, as it learns and it knows. Predicting outcomes, with patterns unseen, Guiding treatments, where once there was none. Yet today, it falters, not without its flaws, For every success, a failure it draws. The complexity of life, not easily tamed, Reminds us that AI is not yet fully named. But look to tomorrow, where potential lies, In AI's embrace, under innovation's skies. Personalized care, tailored to each soul, A future where health is the ultimate goal. From drug discovery to surgical aid, AI's applications are not to be delayed. In the dance of progress, it finds its place, A partner in healing, with a steady grace. So let us embrace this tool of our time, With cautious optimism, and reason and rhyme. For in the hands of those who seek to heal, Generative AI can make the future real.
To view or add a comment, sign in
-
Medical Affairs leaders, Artificial intelligence (AI), and machine learning (ML)- based tools are rapidly becoming more mainstream. Are you having conversations in the fields on this topic? What does that mean for oncologists and their patients? [Or any specialty] Are KOLs comfortable using AI decision models in practice? What concerns them most if you’re hesitating to use these models? #medaff #insights #oncology #AI https://buff.ly/3JuvJ8U
To view or add a comment, sign in
-
In the September Edition Journal of AMIA (American Medical Informatics Association), an article was published on AI for clinical trials. Mendel was highlighted as one of two companies, along with IBM watsonx, and the article highlighted Mendel's transformation of clinical trials: "For instance, in an ongoing oncology trial, the utilization of Mendel.ai led to a 24%-50% increase in the number of patients accurately identified as potentially eligible compared to the standard practice. Furthermore, using Mendel.ai to determine potential eligibility only takes minutes, while it takes an average of 19 days for standard prescreening of breast cancer patients and 263 days for lung cancer patients." Try our product today: https://lnkd.in/gxMa-Tws Read the full article here: https://lnkd.in/gXXgAzmQ
To view or add a comment, sign in
-
Gen AI and Life Sciences, read how Microsoft Gen AI can facilitate the work of the oncologist.
To view or add a comment, sign in
-
#PaperoftheDay: "Rapamycin in the context of Pascal’s Wager: generative pre-trained transformer perspective" DOI ⬇️ https://lnkd.in/e2J4qX-D #cancer #rapamycin #research #openaccess #peerreviewed #publishing
To view or add a comment, sign in
-
🥽Today's paper recommendation Application of Artificial Intelligence in the Diagnosis, Treatment, and Prognostic Evaluation of Mediastinal Malignant Tumors 👥 Jiyun Pang et al. 📖 Read more: https://lnkd.in/ddcPbwfv 📑 This article belongs to the Special Issue Clinical Application of Artificial Intelligence in Cancer Research, Diagnosis and Therapy. For more papers from this Special Issue, please visit: https://lnkd.in/dYjKcKGH
To view or add a comment, sign in
-
#ArtificialIntelligence (AI) in #breastcancer screening is proving to be invaluable, detecting potential issues early on. Anand Mahindra, Chairperson of Mahindra, highlighted the significance of AI, stating, “If this is accurate, then AI is going to be of significantly more value to us than we imagined and much earlier than we had imagined.” Research from Science Translational Medicine emphasizes the predictive nature of risk assessment in computational terms, linking mammogram features to future #cancerdiagnoses. Flynnhealthcare #healthcareAI
To view or add a comment, sign in
-
Artificial intelligence, a new ally in the fight against cancer 🩺 AI is radically transforming the way we fight cancer. ⚔️ By analysing massive amounts of medical data, AI makes it possible to: 👉 Detect tumours earlier 👉 Personalise treatments 👉 Improve prognosis But how does it work? Read on in my article for Blog Economie Numérique 📖
To view or add a comment, sign in
-
The American Society of Clinical Oncology (ASCO) has set six guiding principals for use of AI in Oncology :::: 👥 👀 Transparency – AI tools and applications should be transparent throughout their lifecycle. 💡 Informed Stakeholders – Patients and clinicians should be aware when AI is used in clinical decision-making and patient care. ⚖ Equity and Fairness – Developers and users of AI should protect against bias in AI model design and use and ensure access to AI tools in application. ☑ Accountability – AI systems must comply with legal, regulatory, and ethical requirements that govern the use of data. AI developers should assume responsibility for their AI systems, its decisions, and their adherence to legal, regulatory, and ethical standards. 🔐 Oversight and Privacy – Decision-makers should establish institutional compliance policies that govern the use of AI, including protections that guard clinician and patient autonomy in clinical decision-making and privacy of personal health information. 👤 🫶 Human-Centered Application – Human interaction is a fundamental element of health care delivery; AI does not eliminate the need for human interaction and should not be used as a substitute for sensitive interactions that require it. We applaud ASCO for being at the forefront of setting this type of guidance! The Realyze Intelligence solution fits the bill - we support & adhere to all six of these guiding principals ✅ ✅ ✅ ✅ ✅ ✅ We're ready to help you accelerate clinical trial screening & turbocharge your clinical research. https://lnkd.in/gp3-MH7h #AIOncology #AIinPrecisionOncology #ClinicalTrialInnovation #NoMoreZombieTrials #RealyzeIntelligence
To view or add a comment, sign in
-
Are you Okay with AI helping your doctor? What if it meant being treated faster? OpenAI is expanding its push into healthcare by partnering with startup Color Health to develop an AI assistant that helps doctors with cancer screening and treatment planning. Color Health has created an "AI copilot" using OpenAI's GPT-4 model that can assist doctors in a few keyways: 1. Generating personalized cancer screening plans based on a patient's risk factors and medical history 2. Streamlining the pre-treatment process after a cancer diagnosis, which can often take weeks or months before a patient sees an oncologist The goal is to help doctors work more efficiently and focus on clinical decision-making rather than getting bogged down in administrative tasks. While this technology shows promise, there are some concerns. Doctors must fully control the final outputs and decisions because AI models can have biases and "hallucinate" incorrect information. As AI becomes more integrated into healthcare, patients will need to decide if they are comfortable with an AI assisting their doctor. The benefits could be faster diagnosis and treatment, but the risks of AI errors or biases will need to be carefully managed. https://lnkd.in/g5UQN2cS
To view or add a comment, sign in